Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RETINO 2018: Conservative Treatment for Retinoblastoma
NCT04681417Phase 3Recruiting
- Sponsor
- Institut Curie
- Start
- Mar 2021
- Primary completion
- Jan 2035
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of melphalan and topotecan in retinoblastoma (Rb) (4 arms), sponsored by Institut Curie. Primary endpoints: Rate of eye preservation at 24 months and Visual function based on WHO criteria. Started Mar 2021; status: recruiting.
02
Drugs
melphalantopotecan
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on NCT04681417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04681417.